Skip to main content
Fig. 3 | Journal of Biomedical Science

Fig. 3

From: Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma

Fig. 3

The oncogenic roles of RRM1 and RRM2 in MM.  A Analysis of RRM1 and RRM2 expression in publicly available MM patient data sets from Mayo Clinic (data set GSE6477). Increased RRM1 or RRM2 expression is observed in plasma cells from patients with MGUS, SMM, MM and relapsed MM than from normal healthy donors. B The expression levels of RRM1 and RRM2 were significantly up-regulated in relapsed patients from TT2 and TT3 cohorts in comparison with patients at the baseline stage (based on data set GSE2658). C Kaplan-Meier analyses of OS about patients from TT2 (p < 0.001) and TT3 (p < 0.05) cohorts revealed inferior outcomes among the patients with high (quartiles 4) RRM1 or RRM2 expression compared with the remaining patients with low (quartiles 1–3) RRM1 or RRM2 expression (based on data set GSE2658). D Immunohistochemical analysis of RRM1 and RRM2 expression (positive cells are brown) in 3 representative BM specimens derived from normal and MM patients (ND#1, 5, 8 and MM#1, 7, 14). Original magnification ×20. E MM cell lines were cultured for 6 days and knockdown of RRM1 or RRM2 in MM cell lines induced significant growth inhibition. F MM cell lines were cultured for 6 days and overexpression of RRM1 or RRM2 in MM cell lines induced significant growth increase. G Differences in tumor size between different groups of nude mice on Day 22 after injection of H929 cells. H929 cells transduced with RRM1 or RRM2 shRNA and scramble control vectors were subcutaneously injected into mice (n = 5/group). Tumor volume was quantified and knockdown of RRM1 or RRM2 inhibited tumor growth. All data are expressed as means ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page